|
Indian Pediatr 2014;51: 64-65 |
 |
Vitamin D Treatment and Toxicity: Primum
Non Nocere
|
We read with interest the recent review article on Vitamin D
deficiency and treatment in childhood [1]. Intermittent
dosing with Stoss regimens is effective in the treatment and
prevention of vitamin D deficiency, is much more economical
than daily dosing, and ensures supervised administration and
compliance. However, stoss does not necessarily mean large.
Stoss (German for "bump up") effect can be obtained with
smaller doses than those used currently by pediatricians in
India. Caution needs to be exercised as vitamin D is fat
soluble and accumulates in the body. The resulting
hypercalcemia can be life threatening and hypercalciuria can
result in nephrocalcinosis and renal failure.
The authors quote the study of Gordon,
et al. [2] for the use of 2000 IU daily or 50,000 IU
weekly for 6 weeks. They do not mention that some of the
infants on weekly dose regimen developed toxic levels of 25
OHD by the end of the study. The study of Shah and Finberg,
quoted by the author did not evaluate rigorously for
toxicity. Studies have demonstrated that single oral doses
of 600,000 IU used to treat nutritional rickets in 3-36
months old children led to significant risk of hypercalcemia
[3]. Vanstone, et al. [4] have documented
hypervitaminosis D, hypercalcemia and hypercalciuria in
infants receiving 1400 to 2000 IU of vitamin D daily for 6
to 12 weeks. Thus many expert groups now recommend caution
in treating children with higher doses of vitamin D. The
APEG Australasian Pediatric Endocrine Group specifically
mentions that stoss therapy is not recommended for children
less than 3 months of age; for older children a more
conservative approach of a single initial dose of 50,000 to
150,000 IU is recommended [5].
It is time pediatricians in India stopped
using regimens which employ 6 lakh units, and avoid the risk
of vitamin D toxicity. More emphasis should be laid on
treating children with minimally effective doses.
Kriti Joshi and Vijayalakshmi Bhatia
Department of Endocrinology, Sanjay Gandhi Postgraduate
Institute of Medical Sciences,
Lucknow, Uttar Pradesh, India.
Email:
[email protected]
References
1. Balasubramanian S, Dhanalakshmi K,
Amperayani S. Vitamin D deficiency in childhood-a review of
current guidelines on diagnosis and management. Indian
Pediatr. 2013;50:669-75.
2. Gordon CM, Williams AL, Feldman HJ,
Sinclair L, Vasquez A, Cox JE. Treatment of hypovitaminosis
in infants and toddlers. J Clin Endocrinol Metab.
2008;93:2716–21.
3. Cesur Y, Caksen H, Gundem A, Kirimi E,
Odabas D. Comparison of low and high doses of vitamin D
treatment in nutritional vitamin deficiency rickets. J
Pediatr Endocrinol Metab. 2003;16:1105–9.
4. Vanstone MB, Oberfield SE, Shader L,
Ardeshirpour L, Carpenter TO. Hypercalcemia in children
receiving pharmacologic doses of vitamin D. Pediatrics.
2012;129:e1060-3.
5. Paxton GA, Teale GR, Nowson CA, Mason
RS, McGrath JJ, Thompson MJ, et al. Australian and
New Zealand Bone and Mineral Society; Osteoporosis
Australia..Vitamin D and health in pregnancy, infants,
children and adolescents in Australia and New Zealand: a
position statement. Med J Aust. 2013;198:142-3.
|
Reply |
In children with symptomatic vitamin D deficiency, Stoss
therapy is ideal in situations where adherence to therapy is
questionable, because the doses can be observed. Basic
pharmacology principles suggest that the circulating
half-life is a suitable dosing interval for a drug. Because
vitamin D and 25(OH)D exhibit half-lives in the body that
are in the order of months and weeks, the daily
administration of vitamin is probably unnecessary [1]. None
of the cases of hypercalcemia attributed to vitamin D
supplements reported by Vanstone, et al. [2]. was
symptomatic, and hence their observations might not be
clinically relevant. Gordon, et al. [3] observed a
higher overall incidence of mild hypercalcemia at baseline
in contrast to after treatment, and also reported that all
subjects were asymptomatic.
Emel, et al. [4] recently compared
Stoss theray (150,000 units oral ) with daily dose schedule
(2000 units daily for 6 weeks) in children and reported that
there was no evidence about the increased risk of
hypercalciuria in low-stoss therapy. Higher vitamin D levels
were obtained in low-stoss therapy group. Symptomatic
hypercalcemia due to Stoss therapy (in appropriate doses) in
children with Vitamin D deficiency has not been reported so
far. In our review, Stoss therapy was suggested as an option
only for children more than 1 year of age, and particularly
in situations where lack of compliance is a possibility.
S Balasubramanian
Email: [email protected]
References
1. Vieth R. The Pharmacology of Vitamin
D, Including Fortification Strategies. In: Feldman D,
Glorieux F, Pike JW, eds. Vitamin D. 2005. New York:
Elsevier; p. 995–1015.
2. Vanstone MB, Oberfield SE, Shader L,
Ardeshirpour L, Carpenter TO. Hypercalcemia in children
receiving pharmacologic doses of vitamin D. Pediatrics.
2012;129:e1060-3.
3. Gordon CM, Williams AL, Feldman HJ,
Sinclair L, Vasquez A, Cox JE. Treatment of hypovitaminosis
in infants and toddlers. J Clin Endocrinol Metab.
2008;93:2716-21.
4. Emel T, Dođan DA, Erdem G, Faruk O.
Therapy strategies in vitamin D deficiency with or without
rickets: efficiency of low-dose stoss therapy. J Pediatr
Endocrinol Metab. 2012;25:107-10.
|
|
 |
|